Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: A case-control study

HIV Medicine

Volumn 9, Issue 6, 2008, Pages 427-432

  Wunder, D M ^a   Fux, C A ^a   Bersinger, N A ^a   Mueller, N J ^b   Hirschel, B ^c,i   Cavassini, M ^d,i   Elzi, L ^e,i   Schmid, P ^f,i   Bernasconi, E ^g,i   Mueller, B ^a   Furrer, Hansjakob ^a   Battegay, M ⁱ   Boni J ⁱ   Bucher, H C ⁱ   Burgisser Ph ⁱ   Calmy, A ⁱ   Cattacin, S ⁱ   Dubs, R ⁱ   Egger, M ⁱ   Fischer, M ⁱ   Flepp, M ⁱ   Fontana, A ⁱ   Francioli, P ^d   Fux, C ⁱ   Gorgievski, M ⁱ   Gunthard H ⁱ   Hirsch, H ⁱ   Hosli I ⁱ   Kahlert, Ch ⁱ   Kaiser, L ⁱ   Karrer, U ⁱ   Kind, C ⁱ   Klimkait, Th ⁱ   Ledergerber, B ⁱ   Martinetti, G ⁱ   Martinez, B ⁱ   Muller N ⁱ   Nadal, D ⁱ   Opravil, M ⁱ   Paccaud, F ⁱ   Pantaleo, G ⁱ   Rauch, A ⁱ   Regenass, S ⁱ   Rickenbach, M ^h   Rudin, C ⁱ   Schultze, D ⁱ   Schupbach J ⁱ   Speck, R ⁱ   Taffe P ⁱ   Telenti, A ⁱ   Trkola, A ⁱ   Vernazza, P ⁱ   Weber, R ⁱ   Yerly, S ⁱ   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g Hospital of Lugano   (Switzerland)

^h Data Centre

ⁱ Centre Hospitalier Universitaire Vaudois ^*

Author keywords

Antiretroviral therapy; Dehydroepiandrosterone; Follicle stimulating hormone; Free testosterone; HIV; Lipoatrophy; Lipodystrophy; Luteinizing hormone

Indexed keywords

ANDROGEN; ANTIRETROVIRUS AGENT; FOLLITROPIN; GONADOTROPIN; LAMIVUDINE; LUTEINIZING HORMONE; PRASTERONE; TESTOSTERONE; ZIDOVUDINE;

ADULT; AGE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLITROPIN BLOOD LEVEL; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADULT; ANDROGENS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; GONADOTROPINS; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 47649110068     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00578.x     Document Type: Article

References (34)

1. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84: 611-616.
2. Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: A prospective study. AIDS 1991; 5: 729-733.
3. Wunder DM, Bersinger NA, Fux CA et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 2007; 12: 261-265.
4. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003; 361: 726-735.
5. Vigouroux C, Gharakhanian S, Salhi Y et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diab Metab 1999; 25: 225-232.
6. Walker UA, Bickel M, Lutke Volksbeck SI et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29: 117-121.
7. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-1115.
8. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25-F32.
9. Nolan D, Moore C, Castley A et al. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003; 17: 121-123.
10. Jones SP, Qazi N, Morelese J et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005; 40: 565-572.
11. Lagathu C, Eustace B, Prot M et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12: 489-500.
12. Tarr PE, Telenti A. Toxicogenetics of antiretroviral therapy: Genetic factors that contribute to metabolic complications. Antivir Ther 2007; 12: 999-1013.
13. Wunder D, Bersinger NA, Fux C et al. Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS 2005; 19: 1837-1842.
14. Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001; 34: 107-112.
15. Dube MP, Parker RA, Tebas P et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naïve subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19: 1807-1818.
16. Mylonakis E, Koutkia P, Grinspoon S. Diagnosis and treatment of androgen deficiency in human immunodeficiency virus-infected men and women. Clin Infect Dis 2001; 33: 857-864.
17. Christeff N, Gharakhanian S, Thobie N, Rozenbaum W, Nunez EA. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr 1992; 5: 841-846.
18. Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31: 1240-1244.
19. Collazos J, Martinez E, Mayo J, Ibarra S. Sexual hormones in HIV-infected patients: The influence of antiretroviral therapy. AIDS 2002; 16: 934-937.
20. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56: 1278-1281.
21. Boyce MJ, Baisley KJ, Clark EV, Warrington SJ. Are published normal ranges of serum testosterone too high? Results of a cross-sectional survey of serum testosterone and luteinizing hormone in healthy men. BJU Int 2004; 94: 881-885.
22. Piketty C, Jayle D, Gonzalez-Canali G, Debuire B, Baulieu EE, Kazatchkine MD. Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy. HIV Med 2001; 2: 136-138.
23. Christeff N, Nunez EA, Gougeon ML. Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy. Ann NY Acad Sci 2000; 917: 962-970.
24. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA 2004; 292: 2243-2248.
25. Smith KJ, Skelton HG. Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy. Clin Exp Dermatol 2001; 26: 155-161.
26. Pitteloud N, Hardin M, Dwyer AA et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636-2641.
27. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117: 807-811.
28. Suzuki M, Kanazawa A, Hasegawa M, Hattori Y, Harano Y. A close association between insulin resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension. Endocr J 1999; 46: 521-528.
29. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized, controlled trial. Ann Intern Med 2004; 140: 786-794.
30. van Wijk JP, de Koning EJ, Cabezas MC et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: A randomized trial. Ann Intern Med 2005; 143: 337-346.
31. Coll B, van Wijk JP, Parra S et al. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. Eur J Pharmacol 2006; 544: 104-110.
32. Feldt T, Oette M, Kroidl A et al. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Infection 2006; 34: 55-61.
33. Carr A, Workman C, Carey D et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet 2004; 363: 429-438.
34. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007; 195: 1754-1761.